ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.13
1.17%
Dow Jones
39,908.07
0.88%
US Dollar vs MXN
16.69048
-0.93%
Brent Oil
82.73
0.22%
Bitcoin
66,041.02
7.30%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. 23andMe Holding Company (ME)

  7. 23andMe Holding Company (ME) Noticias

ME

23andMe (ME)

23andMe Holding Company
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ME
FechaHoraFuenteTítuloSímboloCompañía
14/05/202406:00GlobeNewswire Inc.Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros PharmaceuticalsNASDAQ:ME23andMe Holding Company
10/05/202415:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ME23andMe Holding Company
09/05/202415:50GlobeNewswire Inc.23andMe to Report Q4 and Full Year FY2024 Financial ResultsNASDAQ:ME23andMe Holding Company
30/04/202410:00Business WirePotter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach CaseNASDAQ:ME23andMe Holding Company
24/04/202415:05GlobeNewswire Inc.23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:ME23andMe Holding Company
18/04/202407:00GlobeNewswire Inc.23andMe announces CEO’s intention to pursue a potential take-privateNASDAQ:ME23andMe Holding Company
05/04/202415:05GlobeNewswire Inc.23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ME23andMe Holding Company
20/03/202406:30GlobeNewswire Inc.23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6NASDAQ:ME23andMe Holding Company
19/03/202407:00GlobeNewswire Inc.23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years AgoNASDAQ:ME23andMe Holding Company
06/03/202406:30GlobeNewswire Inc.23andMe Launches New Genetic Reports on Common Forms of CancerNASDAQ:ME23andMe Holding Company
05/03/202415:30GlobeNewswire Inc.23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ME23andMe Holding Company
21/02/202415:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ME23andMe Holding Company
07/02/202415:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ME23andMe Holding Company
07/02/202415:01GlobeNewswire Inc.23andMe Reports Third Quarter Fiscal 2024 Financial ResultsNASDAQ:ME23andMe Holding Company
06/02/202406:00Business WireMoneta Gold and Nighthawk Gold Complete At-Market Merger to form STLLR Gold Inc.NASDAQ:ME23andMe Holding Company
30/01/202421:12GlobeNewswire Inc.23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernayNASDAQ:ME23andMe Holding Company
30/01/202416:00Business WireNighthawk Gold Obtains Final Court Order for the Proposed ArrangementNASDAQ:ME23andMe Holding Company
24/01/202415:05GlobeNewswire Inc.23andMe to Report FY2024 Third Quarter Financial ResultsNASDAQ:ME23andMe Holding Company
22/01/202407:00Business WireMoneta Gold and Nighthawk Gold Announce the Proposed Directors for the MergeCo BoardNASDAQ:ME23andMe Holding Company
19/12/202307:00GlobeNewswire Inc.23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohortsNASDAQ:ME23andMe Holding Company
01/12/202315:06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ME23andMe Holding Company
28/11/202306:15Business WireNighthawk and Moneta Announce At-Market Merger to Create a Leading Canadian Gold Development CompanyNASDAQ:ME23andMe Holding Company
08/11/202315:05GlobeNewswire Inc.23andMe Reports Second Quarter Fiscal 2024 Financial ResultsNASDAQ:ME23andMe Holding Company
07/11/202307:00GlobeNewswire Inc.23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health MembershipNASDAQ:ME23andMe Holding Company
06/11/202307:00GlobeNewswire Inc.23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1NASDAQ:ME23andMe Holding Company
31/10/202307:00GlobeNewswire Inc.23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health DataNASDAQ:ME23andMe Holding Company
30/10/202307:00GlobeNewswire Inc.23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSKNASDAQ:ME23andMe Holding Company
25/10/202315:05GlobeNewswire Inc.23andMe to Report FY2024 Second Quarter Financial ResultsNASDAQ:ME23andMe Holding Company
27/09/202315:05GlobeNewswire Inc.23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual MeetingNASDAQ:ME23andMe Holding Company
15/09/202315:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ME23andMe Holding Company
 Showing the most relevant articles for your search:NASDAQ:ME

Su Consulta Reciente

UNSW3
SAITOUSDT
SAITO
AMEX
ADGE
LSE
PHD
Proactis
COIN
CLOUSD
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados